AICAR

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is a small molecule, not a classic peptide, despite often being grouped with research peptides in catalogs. It is a naturally occurring intermediate in the purine biosynthesis pathway and is best known in research as an activator of AMP-activated protein kinase (AMPK).

Because AMPK acts as a cellular "energy sensor," AICAR has been explored in preclinical settings as a so-called exercise mimetic — a compound hypothesized to reproduce some metabolic signals normally triggered by physical activity. Claims made in commercial and athletic contexts frequently go well beyond what controlled human evidence supports.

AICAR is taken up by cells and phosphorylated to ZMP, a compound that mimics AMP and thereby activates AMPK. Proposed downstream themes, drawn largely from preclinical models, include:

• Activation of AMPK, a central regulator of cellular energy balance
• Signaling associated with mitochondrial biogenesis and oxidative capacity
• Increased glucose uptake in muscle tissue independent of insulin signaling
• Shifts toward fatty-acid oxidation and away from energy storage

How reliably these cellular effects translate into meaningful endurance, metabolic, or body-composition outcomes in humans remains an open research question rather than an established fact.

AICAR is not an approved medicine for performance enhancement, weight management, or metabolic disease in general clinical use. It has appeared primarily as a laboratory reagent and as an investigational agent in research on metabolism and ischemia-related contexts.

Much of the public interest stems from animal studies suggesting endurance-related effects. Extrapolating those findings to healthy humans is not supported by robust clinical trials, and any consideration of AICAR should be grounded in local regulations and the distinction between exploratory research and validated therapy.

AICAR is the lead named example of S4.4.1 on the WADA Prohibited List — "activators of the AMP-activated protein kinase (AMPK)" — which sits inside S4.4, Metabolic Modulators, alongside PPARδ agonists such as GW1516 (S4.4.1), insulins and insulin-mimetics (S4.4.2), meldonium (S4.4.3) and trimetazidine (S4.4.4). Substances in classes S4.3 and S4.4 are non-Specified, so a first violation carries a four-year default sanction.

USADA states the rationale directly: AICAR "is prohibited because it's an AMPK activator, which are prohibited at all times under the category of Hormone and Metabolic Modulators on the WADA Prohibited List because of their potential performance-enhancing effects," and notes that it "is an experimental compound that is not yet approved for therapeutic use in humans" (USADA athlete guidance).

Two practical points follow. First, the same bullet also captures MOTS-c, so an AMPK-activating peptide is prohibited on mechanism, not on name. Second, AICAR is produced endogenously in healthy humans and excreted in urine, so laboratories cannot simply screen for presence. A reference study of 499 elite-athlete doping-control samples found a mean urinary AICAR concentration of 2,186 ng/mL with a standard deviation of 1,655 ng/mL, varying by sex, sport and whether collection was in or out of competition (Thomas et al., Anal Bioanal Chem 2010). With inter-individual variance that wide, a concentration threshold alone cannot prove administration, which is why confirmation relies on carbon-isotope-ratio (¹³C/¹²C) methods that distinguish synthetic AICAR from the body's own — an approach reported to detect a single oral AICAR administration for more than 40 hours (Piper et al., Rapid Commun Mass Spectrom 2014). That analytical difficulty — not any gap in the rules — is why AICAR findings are reported far less often than the compound's availability would suggest.

Because AICAR influences purine metabolism, one recurring theoretical concern is its potential relationship to uric acid handling. As with other investigational compounds, nonspecific effects and interindividual variability are possible, and long-term safety across diverse populations is not well characterized.

Attention to product sourcing, regulatory guidance, and individual risk factors is important. High-level summaries cannot substitute for rigorous safety evaluation.

AICAR is a nucleoside analog that acts intracellularly after conversion to ZMP. Its pharmacology is shaped by cellular uptake, its relatively short duration of activity in some models, and the fact that it engages a broad, systemic energy-sensing pathway rather than a single narrow target.

This information summarizes conceptual pharmacology and does not constitute medical advice or a usage recommendation.

AICAR has a pharmaceutical identity most catalog listings omit: under the International Nonproprietary Name acadesine, the same molecule was formulated and manufactured to clinical-trial standard and given intravenously to thousands of surgical patients. That program is the only place a defined AICAR formulation and dosing regimen has ever existed — 0.1 mg/kg per minute for seven hours, plus addition to cardioplegic solution, in the phase 3 RED-CABG trial (Newman et al., JAMA, 2012). Acadesine was also taken into a phase 1/2 dose-escalation study in B-cell chronic lymphocytic leukemia (NCT00559624).

Nothing about those programs carries over to reconstituted powder sold for research use. The trials used continuous intravenous infusion under anesthesia with pharmacy-controlled preparation; the endurance findings that drive consumer interest came from oral dosing in mice over four weeks (Narkar et al., Cell, 2008). There is no published human protocol for any performance or body-composition purpose, by any route.

AICAR is also grouped with peptides it does not resemble chemically. It is a nucleoside — a purine-biosynthesis intermediate — not an amino-acid chain. The one thing it genuinely shares with a peptide on this site is a mechanism: MOTS-c also activates AMPK, which is why both fall under the same clause of the WADA Prohibited List.

Research on AICAR has examined AMPK activation, mitochondrial biogenesis, glucose uptake, and endurance-related endpoints, primarily in cell and animal models. Some rodent studies generated significant interest in the idea of an "exercise in a pill" concept, but questions about effect size, delivery, and human translation remain.

Because the evidence base is largely preclinical and the human data are limited, claims about AICAR should be interpreted cautiously. High-level overviews are not a substitute for critical appraisal of primary data.

For deeper dives on this compound, see:

• AICAR benefits and areas of interest
• AICAR side effects and safety context
• AICAR dosing concepts (educational)
• AICAR research and evidence overview

Where does the "exercise in a pill" idea come from? From one specific mouse experiment. Salk Institute researchers gave sedentary mice AICAR orally for four weeks with no training, and running endurance increased by 44% alongside induction of metabolic genes; the paper was titled "AMPK and PPARdelta agonists are exercise mimetics" (Narkar et al., Cell, 2008). Almost every downstream claim traces to that result. It is a real, well-published finding — in mice, on a treadmill, with no human replication.

Has AICAR ever been given to humans? Yes, on a large scale, which is the fact usually missing from the marketing. As acadesine, AICAR was tested in RED-CABG, a randomized, double-blind, placebo-controlled phase 3 trial at 300 sites in 7 countries in patients undergoing coronary artery bypass surgery. It was stopped early for futility after 3,080 of a planned 7,500 patients were randomized: the primary composite of death, nonfatal stroke, or severe left ventricular dysfunction occurred in 5.1% on acadesine versus 5.0% on placebo (odds ratio 1.01, 95% CI 0.73–1.41), with no differences in key secondary endpoints (Newman et al., JAMA, 2012; NCT00872001). The indication was ischemia-reperfusion injury, not performance — but the molecule has been through a serious human program and did not become a drug.

Does it improve endurance in people? No trial has tested that. There is no published human study of AICAR for endurance, VO₂ max, body composition, or training adaptation, so the honest answer is that the headline benefit has never been measured in the species it is sold to.

Why is it banned, and why are AICAR positives so rare? AICAR is the lead named example under S4.4.1 of the WADA Prohibited List, "activators of the AMP-activated protein kinase (AMPK)", prohibited at all times. Detection is the hard part: AICAR is produced endogenously and excreted in urine, and in 499 elite-athlete doping-control samples the mean urinary concentration was 2,186 ng/mL with a standard deviation of 1,655 ng/mL (Thomas et al., Anal. Bioanal. Chem., 2010). With natural variation that wide, no concentration threshold can prove administration, so confirmation depends on carbon-isotope-ratio analysis distinguishing synthetic from endogenous AICAR — reported to detect a single oral dose for more than 40 hours (Piper et al., Rapid Commun. Mass Spectrom., 2014). The scarcity of findings reflects analytical difficulty, not permissiveness.

Is AICAR a peptide? No. It is 5-aminoimidazole-4-carboxamide ribonucleotide, a nucleoside intermediate in purine biosynthesis. Cells take it up and phosphorylate it to ZMP, which structurally mimics AMP and activates AMPK. It is catalogued with peptides for commercial reasons, not chemical ones.

What is the practical difference between AMPK activation and exercise? Exercise activates AMPK, but it also does a great deal more — mechanical loading, cardiovascular work, hormonal and neural adaptation. AICAR engages one node of that network systemically, in every tissue that takes it up, including tissues exercise would not have recruited. That breadth is why the Cell 2008 result was interesting and also why a mouse endurance number does not translate into a predictable human effect.